Amarin’s regulatory fortunes haven’t improved in the new year, as the FDA has again put off a decision on the company’s fish oil pill for high cholesterol, indefinitely postponing a final approval on the troubled drug.

…read more

Source: Amarin endures another FDA delay as Vascepa languishes


0 No comments